BET联合PI3K与NF-κB抑制剂三联方案在成人T细胞白血病/淋巴瘤中显示协同活性
本研究利用异种移植、离体和体外模型,探讨BET抑制剂I-BET762联合PI3K抑制剂copanlisib及NF-κB抑制剂巴多索隆甲基对成人T细胞白血病/淋巴瘤(ATL)细胞的协同作用。三联方案通过下调c-MYC、上调GILZ并增强凋亡,显著抑制ATL细胞生长,延长荷瘤小鼠生存,并抑制急性和冒烟型/慢性ATL患者外周血单个核细胞中ATL细胞的增殖。
要点
- I-BET762与copanlisib及巴多索隆甲基三联在ATL模型中显示协同活性。
- 三联方案下调c-MYC、上调GILZ,并升高活性caspase-3和cleaved PARP。
- 三联方案延长ATL异种移植小鼠生存并抑制患者PBMCs中ATL细胞增殖。
核心结论
- 数据为探索BET、PI3K/AKT和NF-κB抑制剂多药联合治疗ATL患者的临床试验提供了依据。
- 该联合方案扩展了这种难治性恶性肿瘤的潜在治疗选择。
研究设计与样本
- 研究使用异种移植、离体和体外模型评估药物联合效果。
- 体外和离体实验使用ATL细胞系及急性和冒烟型/慢性ATL患者外周血单个核细胞(PBMCs)。
- 体内实验使用荷ATL异种移植小鼠模型。
主要发现
- I-BET762(BETi)与copanlisib(PI3Ki)及巴多索隆甲基(NF-κBi)联用显著降低ATL细胞生长。
- 三联方案协同活性表现为下调c-MYC表达并上调糖皮质激素诱导亮氨酸拉链(GILZ)水平。
- 三联方案通过升高活性caspase-3和cleaved PARP表达增强凋亡诱导。
- 三联方案延长荷ATL异种移植小鼠的生存并抑制急性和冒烟型/慢性ATL患者PBMCs中ATL细胞的增殖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell lymphoproliferative malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). ATL is an orphan disease with no curative drug treatment regimens urgently needing new combination therapy. HTLV-1-infected cells rely on viral proteins, Tax and HBZ (HTLV-1-b-ZIP factor), to activate the transcription of various host genes that are critical for promoting leukemic transformation. Inhibition of bromodomain and extraterminal motif (BET) protein was previously shown to collapse the transcriptional network directed by BATF3 super-enhancer and thereby induced ATL cell apoptosis. In the current work, by using xenograft, ex vivo, and in vitro models, we demonstrated that I-BET762 (BETi) synergized with copanlisib (PI3Ki) and bardoxolone methyl (NF-κBi) to dramatically decrease the growth of ATL cells. Mechanistically, the triple combination exhibited synergistic activity by down-regulating the expression of c-MYC while upregulating the level of the glucocorticoid-induced leucine zipper (GILZ). The triple combination also enhanced apoptosis induction by elevating the expression of active caspase-3 and cleaved PARP. Importantly, the triple combination prolonged the survival of ATL-bearing xenograft mice and inhibited the proliferation of ATL cells from peripheral blood mononuclear cells (PBMCs) of both acute and smoldering/chronic ATL patients. Therefore, our data provide the rationale for a clinical trial exploring the multiagent combination of BET, PI3K/AKT, and NF-κB inhibitors for ATL patients and expands the potential treatments for this recalcitrant malignancy.
引用
- Daenthanasanmak A, Bamford RN, Yoshioka M, et al. Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. Blood Adv. 2022. PMID: 35030628. doi:10.1182/bloodadvances.2021005948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。